Latham John A 4
4 · ALDER BIOPHARMACEUTICALS INC · Filed Aug 2, 2018
Insider Transaction Report
Form 4
Latham John A
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2018-08-01$3.46/sh+24,999$86,622→ 268,692 total - Sale
Common Stock
2018-08-01$19.55/sh−24,999$488,768→ 243,693 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-08-01−24,999→ 43,184 totalExercise: $3.46Exp: 2022-06-12→ Common Stock (24,999 underlying)
Footnotes (4)
- [F1]The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.90 to $19.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
- [F4]The shares subject to this stock option are fully vested.